Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Sells $58,487.52 in Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 9,373 shares of Relay Therapeutics stock in a transaction that occurred on Thursday, June 27th. The shares were sold at an average price of $6.24, for a total transaction of $58,487.52. Following the sale, the chief financial officer now owns 330,430 shares in the company, valued at approximately $2,061,883.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Thomas Catinazzo also recently made the following trade(s):

• On Monday, April 29th, Thomas Catinazzo sold 1,695 shares of Relay Therapeutics stock. The shares were sold at an average price of $6.38, for a total transaction of $10,814.10.

Relay Therapeutics Trading Down 1.8 %

Relay Therapeutics stock traded down $0.12 during mid-day trading on Monday, reaching $6.40. The company’s stock had a trading volume of 1,870,437 shares, compared to its average volume of 1,227,672. The firm has a market cap of $849.55 million, a price-to-earnings ratio of -2.42 and a beta of 1.66. The business has a 50 day moving average price of $6.81 and a 200-day moving average price of $8.52. Relay Therapeutics, Inc. has a twelve month low of $5.70 and a twelve month high of $13.32.

Relay Therapeutics (NASDAQ:RLAY) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.08. The business had revenue of $10.01 million during the quarter, compared to analyst estimates of $0.12 million. The business’s revenue for the quarter was up 4327.9% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.78) EPS. On average, equities analysts expect that Relay Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on RLAY. Barclays upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and set a $15.00 price objective on the stock in a research note on Friday, May 10th. Oppenheimer reissued an “outperform” rating and set a $25.00 price target (down previously from $33.00) on shares of Relay Therapeutics in a research report on Monday, May 6th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Relay Therapeutics in a research report on Friday, June 7th. Finally, JMP Securities reissued a “market outperform” rating and set a $24.00 price target on shares of Relay Therapeutics in a research report on Monday, May 6th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Relay Therapeutics has an average rating of “Buy” and an average price target of $22.80.

Institutional Investors Weigh In On Relay Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC bought a new stake in Relay Therapeutics in the first quarter valued at $79,000. Virtu Financial LLC bought a new stake in Relay Therapeutics in the first quarter valued at $87,000. Victory Capital Management Inc. bought a new stake in Relay Therapeutics in the fourth quarter valued at $126,000. Quest Partners LLC bought a new stake in Relay Therapeutics in the fourth quarter valued at $147,000. Finally, Los Angeles Capital Management LLC lifted its stake in Relay Therapeutics by 25.7% in the first quarter. Los Angeles Capital Management LLC now owns 13,939 shares of the company’s stock valued at $116,000 after buying an additional 2,850 shares during the last quarter. 96.98% of the stock is currently owned by institutional investors.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.